Belvedere Trading
RXDX

Belvedere Trading’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Belvedere Trading’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,100
Closed -$118K – 1242
2023
Q1 		$118K Sell
1,100
-2,100
-66% -$242K ﹤0.01% 438
2022
Q4 		$352K Buy
+3,200
New +$208K ﹤0.01% 186

Other funds holding RXDX

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FCA
FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Belvedere Trading's RXDX Position: Q2 2023 in Review

Belvedere Trading sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,218 shares — an estimated $131K sold.

Belvedere Trading first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $354K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

  • Belvedere Trading reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 1,218 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $131K.
  • Belvedere Trading first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Belvedere Trading's Prometheus Biosciences, Inc. Common Stock position peaked at $354K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.